"Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in"...
Occasional mild adverse events have been noted in association with the use of SecreFlo™ (secretin) in clinical studies of over 957 patients and 24 volunteer subjects.
TABLE 1: ADVERSE EVENTS
|EVENT||SecreFlo™ n = 981
|Abdominal cramps||2 (2)|
|Abdominal discomfort||7 (7)|
|Bleeding - sphincterectomy||6 (6)|
|Bleeding - upper GI 2º to endoscopic abrasion||2 (2)|
|Bradycardia (mild)||2 (2)|
|Burning in stomach||3 (2)|
|Decreased blood pressure||6 (5)|
|Endoscopic perforation of pancreatic duct||2 (2)|
|Hot Sensation||1 (1)|
|Hunger Pangs||1 (1)|
|Leukocytoplastic Vasculitis||1 (1)|
|Numbness/Tingling in extremeties||2 (1)|
|Possible seizure||1 (1)|
|Rash -abdominal||1 (1)|
|Thready pulse||1 (1)|
|Transient low O2 saturation||1 (1)|
|Transient respiratory distress||2 (2)|
|Urticaria 2º contrast material (prior to secretin administration)||1 (1)|
|Total Patients with AE's (%)||73 (7.4)|
Read the SecreFlo (secretin) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 11/21/2008
Additional SecreFlo Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.